Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Income (2020 - 2025)

Tango Therapeutics has reported Non Operating Income over the past 6 years, most recently at $1.4 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 6.5% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $5.3 million, down 30.26%, while the annual FY2025 figure was $4.1 million, 46.54% down from the prior year.
  • Non Operating Income for Q4 2025 was $1.4 million at Tango Therapeutics, up from $705000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $3.4 million in Q3 2023 and troughed at -$380000.0 in Q4 2021.
  • A 5-year average of $1.2 million and a median of $1.3 million in 2023 define the central range for Non Operating Income.
  • Biggest five-year swings in Non Operating Income: crashed 445.45% in 2021 and later surged 5102.0% in 2023.
  • Year by year, Non Operating Income stood at -$380000.0 in 2021, then skyrocketed by 510.0% to $1.6 million in 2022, then surged by 32.28% to $2.1 million in 2023, then fell by 28.38% to $1.5 million in 2024, then decreased by 6.5% to $1.4 million in 2025.
  • Business Quant data shows Non Operating Income for TNGX at $1.4 million in Q4 2025, $705000.0 in Q3 2025, and $2.1 million in Q2 2025.